secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-05-26T15:00:21+00:00
Accession:  0001193125-26-238237
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M
--------------------------------------------------------------------------------

- ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
- Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.
- Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).
- Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.
- Data from non-GLP mouse studies only; ALN1003 has not been tested in humans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/0001193125-26-238237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-238237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer